Wegovy’s pill formulation brings GLP-1 weight-management therapy to a broader audience.
Wegovy’s new oral formulation is now available nationwide, marking the first GLP-1 pill approved for chronic weight management in adults with obesity. The FDA cleared the 25 mg tablet on December 22, and starter doses began shipping to more than 70,000 pharmacies on January 5.
What’s New
The oral version delivers weight loss results similar to the injectable form. In OASIS-4, adults who remained on treatment lost about 17% of baseline weight, compared to roughly 3% on placebo. Cash-pay patients can start at $149 per month, while commercially insured patients may qualify for a $25 copay savings program.
How to Take It
Endocrinologists emphasize that the pill only works when taken correctly.
- Take on an empty stomach with 4 ounces or less of water.
- No food, no coffee, and no other medications for 30 minutes.
- Do not split or double doses.
"[T]his is a medication that needs to be taken exactly as directed. And if it's not taken correctly, it may not work at all. It may be just a very expensive placebo."
- Scott Isaacs, MD
Diabetes Dialogue reinforces this point. The hosts note that the pill’s effectiveness depends on precise administration and that real-world use will hinge on patients receiving clear, consistent education.
Why This Matters
The daily pill format lowers barriers for people hesitant about injectables and removes cold-chain requirements. But it introduces the challenge of adhering to strict dosing instructions. For people already managing busy mornings, caffeine habits, or multiple medications, the 30-minute fasting window may determine whether the drug works as intended. Absorption determines how much semaglutide enters the system, which directly affects whether patients see meaningful weight loss.
What to Watch
Diabetes Dialogue raises a scenario that has not appeared in most early coverage:
Insurers may require patients to try and fail the oral GLP-1 before covering injectable therapy, especially for weight-loss indications. This would mirror step-therapy structures already used in other therapeutic areas. Given the price difference between the pill’s starter dose ($149/month) and the injectable’s list price (~$1,400/month), the incentive is clear.
Coverage remains inconsistent, and 2025 saw many insurers tighten restrictions on weight-loss drugs. If step-therapy emerges, it could change how people enter GLP-1 treatment and influence which patients ultimately progress to injectable options.
The Broader Picture
Novo Nordisk positions the pill as a way to meet people “no matter how they choose to receive their care,” calling the launch a milestone in obesity treatment. Early commentary suggests the oral option may expand access but will require clear patient education and close policy monitoring.
Sources
